Annual Total Expenses
$23.32 M
-$15.00 M-39.15%
December 31, 2023
Summary
- As of February 7, 2025, RSLS annual total expenses is $23.32 million, with the most recent change of -$15.00 million (-39.15%) on December 31, 2023.
- During the last 3 years, RSLS annual total expenses has fallen by -$439.00 thousand (-1.85%).
- RSLS annual total expenses is now -42.90% below its all-time high of $40.83 million, reached on December 31, 2021.
Performance
RSLS Total Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Total Expenses
$4.05 M
+$34.00 K+0.85%
September 30, 2024
Summary
- As of February 7, 2025, RSLS quarterly total expenses is $4.05 million, with the most recent change of +$34.00 thousand (+0.85%) on September 30, 2024.
- Over the past year, RSLS quarterly total expenses has dropped by -$1.21 million (-22.92%).
- RSLS quarterly total expenses is now -78.32% below its all-time high of $18.69 million, reached on September 30, 2021.
Performance
RSLS Quarterly Total Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Total Expenses Formula
Total Expenses = Cost of Goods Sold + Operating Expenses + Non Operating Expenses
RSLS Total Expenses Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -39.1% | -22.9% |
| 3 y3 years | -1.9% | -78.3% |
| 5 y5 years | -7.3% | -29.8% |
RSLS Total Expenses Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -42.9% | at low | -65.5% | +4.5% |
| 5 y | 5-year | -42.9% | at low | -78.3% | +4.5% |
| alltime | all time | -42.9% | +109.1% | -78.3% | +12.0% |
ReShape Lifesciences Total Expenses History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $4.05 M(+0.8%) |
| Jun 2024 | - | $4.02 M(-3.2%) |
| Mar 2024 | - | $4.15 M(+7.1%) |
| Dec 2023 | $23.32 M(-39.1%) | $3.88 M(-26.3%) |
| Sep 2023 | - | $5.26 M(-16.0%) |
| Jun 2023 | - | $6.26 M(-20.9%) |
| Mar 2023 | - | $7.92 M(-5.1%) |
| Dec 2022 | $38.32 M(-6.2%) | $8.34 M(+8.8%) |
| Sep 2022 | - | $7.67 M(-34.8%) |
| Jun 2022 | - | $11.76 M(+11.4%) |
| Mar 2022 | - | $10.55 M(+11.9%) |
| Dec 2021 | $40.83 M(+71.9%) | $9.43 M(-49.5%) |
| Sep 2021 | - | $18.69 M(+158.5%) |
| Jun 2021 | - | $7.23 M(+32.0%) |
| Mar 2021 | - | $5.48 M(-14.6%) |
| Dec 2020 | $23.76 M(-23.3%) | $6.41 M(+11.0%) |
| Sep 2020 | - | $5.77 M(+22.9%) |
| Jun 2020 | - | $4.70 M(-31.6%) |
| Mar 2020 | - | $6.87 M(+2.9%) |
| Dec 2019 | $30.98 M(+23.2%) | $6.68 M(-12.5%) |
| Sep 2019 | - | $7.63 M(-18.3%) |
| Jun 2019 | - | $9.35 M(+27.7%) |
| Mar 2019 | - | $7.32 M(+60.3%) |
| Dec 2018 | $25.15 M(-12.1%) | $4.57 M(-13.9%) |
| Sep 2018 | - | $5.30 M(-16.9%) |
| Jun 2018 | - | $6.38 M(-28.2%) |
| Mar 2018 | - | $8.90 M(+2.8%) |
| Dec 2017 | $28.62 M(+21.4%) | $8.65 M(+46.2%) |
| Sep 2017 | - | $5.92 M(-15.0%) |
| Jun 2017 | - | $6.97 M(-1.6%) |
| Mar 2017 | - | $7.08 M(+65.8%) |
| Dec 2016 | $23.58 M(-16.3%) | $4.27 M(-10.3%) |
| Sep 2016 | - | $4.76 M(-31.3%) |
| Jun 2016 | - | $6.93 M(-8.9%) |
| Mar 2016 | - | $7.61 M(-1.1%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2015 | $28.16 M(+10.0%) | $7.70 M(+26.8%) |
| Sep 2015 | - | $6.07 M(-18.1%) |
| Jun 2015 | - | $7.42 M(+6.5%) |
| Mar 2015 | - | $6.96 M(+14.4%) |
| Dec 2014 | $25.59 M(+3.5%) | $6.09 M(+8.8%) |
| Sep 2014 | - | $5.59 M(-23.9%) |
| Jun 2014 | - | $7.35 M(+12.1%) |
| Mar 2014 | - | $6.56 M(+2.9%) |
| Dec 2013 | $24.73 M(+8.2%) | $6.37 M(+6.8%) |
| Sep 2013 | - | $5.97 M(-1.7%) |
| Jun 2013 | - | $6.07 M(-3.9%) |
| Mar 2013 | - | $6.32 M(-6.5%) |
| Dec 2012 | $22.86 M(-9.5%) | $6.76 M(+21.3%) |
| Sep 2012 | - | $5.57 M(+13.3%) |
| Jun 2012 | - | $4.92 M(-12.3%) |
| Mar 2012 | - | $5.61 M(-28.9%) |
| Dec 2011 | $25.26 M(+56.1%) | $7.89 M(+10.5%) |
| Sep 2011 | - | $7.13 M(+32.6%) |
| Jun 2011 | - | $5.38 M(+10.8%) |
| Mar 2011 | - | $4.86 M(+34.2%) |
| Dec 2010 | $16.18 M(-33.2%) | $3.62 M(-11.6%) |
| Sep 2010 | - | $4.09 M(-0.5%) |
| Jun 2010 | - | $4.11 M(-5.4%) |
| Mar 2010 | - | $4.35 M(-13.3%) |
| Dec 2009 | $24.21 M(-33.2%) | $5.02 M(-31.0%) |
| Sep 2009 | - | $7.27 M(+16.5%) |
| Jun 2009 | - | $6.23 M(+9.4%) |
| Mar 2009 | - | $5.70 M(-11.9%) |
| Dec 2008 | $36.27 M(+29.4%) | $6.47 M(-35.7%) |
| Sep 2008 | - | $10.06 M(-10.4%) |
| Jun 2008 | - | $11.23 M(+31.8%) |
| Mar 2008 | - | $8.52 M(-1.8%) |
| Dec 2007 | $28.03 M(+54.7%) | $8.67 M(+34.4%) |
| Sep 2007 | - | $6.45 M |
| Dec 2006 | $18.12 M(+62.5%) | - |
| Dec 2005 | $11.15 M | - |
FAQ
- What is ReShape Lifesciences annual total expenses?
- What is the all time high annual total expenses for ReShape Lifesciences?
- What is ReShape Lifesciences annual total expenses year-on-year change?
- What is ReShape Lifesciences quarterly total expenses?
- What is the all time high quarterly total expenses for ReShape Lifesciences?
- What is ReShape Lifesciences quarterly total expenses year-on-year change?
What is ReShape Lifesciences annual total expenses?
The current annual total expenses of RSLS is $23.32 M
What is the all time high annual total expenses for ReShape Lifesciences?
ReShape Lifesciences all-time high annual total expenses is $40.83 M
What is ReShape Lifesciences annual total expenses year-on-year change?
Over the past year, RSLS annual total expenses has changed by -$15.00 M (-39.15%)
What is ReShape Lifesciences quarterly total expenses?
The current quarterly total expenses of RSLS is $4.05 M
What is the all time high quarterly total expenses for ReShape Lifesciences?
ReShape Lifesciences all-time high quarterly total expenses is $18.69 M
What is ReShape Lifesciences quarterly total expenses year-on-year change?
Over the past year, RSLS quarterly total expenses has changed by -$1.21 M (-22.92%)